ArriVent Advances Firmonertinib Toward Pivotal EGFR Exon 20 NSCLC Data as ADC Pipeline Progresses
核心洞察
ArriVent BioPharma expects topline data from the global pivotal FURVENT Phase 3 trial of firmonertinib (搜索) in first-line EGFR (搜索) exon 20 insertion mutant NSCLC in the second half of 2026.
The company advanced ARR-217 (搜索), a CDH17 (搜索)-targeted ADC for gastrointestinal cancers, into Phase 1b dose optimization and plans first-patient dosing for ARR-002, a dual-targeting MUC16 (搜索)/NaPi2b (搜索) ADC, in Q3 2026.
Firmonertinib (搜索) holds FDA Breakthrough Therapy and Orphan Drug designations and is also being studied in the ALPACCA Phase 3 trial for EGFR (搜索) PACC-mutant NSCLC.
ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported second quarter 2026 financial results and highlighted progress across its oncology pipeline, anchored by the anticipated topline readout from the global pivotal FURVENT Phase 3 trial of firmonertinib (搜索) in first-line EGFR (搜索) exon 20 insertion mutant non-small cell lung cancer (搜索) (NSCLC), expected in the second half of 2026.
"FURVENT and ALPACCA global pivotal trials have the potential to establish firmonertinib (搜索) as a first-line treatment option for uncommon EGFR (搜索) mutations in non-small cell lung cancer (搜索) (NSCLC), addressing a significant unmet need for patients who remain underserved by current therapies," said Bing Yao, CEO of ArriVent. "In parallel, we continue to build a differentiated ADC portfolio, with ARR-217 (搜索) advancing into dose optimization and ARR-002 advancing in clinical development."
Firmonertinib: A Mutation-Selective EGFR Inhibitor
Firmonertinib (搜索) is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR (搜索)) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. In March 2021, firmonertinib was approved in China for first-line advanced NSCLC with EGFR exon 19 deletion or L858R mutations, as well as for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation.
The drug has received U.S. FDA Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR (搜索) exon 20 insertion mutations, and U.S. FDA Orphan Drug Designation for the treatment of NSCLC with EGFR mutations or HER2 or HER4 mutations.
The ongoing pivotal Phase 3 study in frontline EGFR (搜索) exon 20 insertion mutant NSCLC is supported by preclinical data for firmonertinib (搜索), with high-resolution crystal structure data showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
FURVENT and ALPACCA Pivotal Trials
FURVENT (NCT05607550) is a global, pivotal three-arm Phase 3 clinical trial of firmonertinib (搜索) in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations, conducted jointly with partner Allist. The trial assesses the safety and efficacy of firmonertinib administered at either 160 mg or 240 mg once daily, with each dose compared to platinum-based chemotherapy with pemetrexed, the current first-line standard of care.
The primary endpoint is progression-free survival (PFS) by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary endpoints in patients with brain metastases at baseline include brain-specific CNS overall response rate (CNS-ORR) and CNS-PFS by modified RECIST (mRECIST). The study enrolled 398 patients globally, including from sites in the United States, Europe and certain Asian countries including Japan and China.
ALPACCA (NCT07185997) is a global, pivotal two-arm Phase 3 clinical trial of firmonertinib (搜索) in first-line non-squamous locally advanced or metastatic NSCLC patients with PACC mutations, also conducted jointly with Allist. The trial evaluates firmonertinib 240 mg once daily versus investigator's choice of osimertinib or afatinib. The 240 mg dose was selected for pivotal development based on data from the FURTHER trial (NCT05364073) showing a 16-month median PFS and a confirmed 68% ORR by BICR. The primary endpoints of ALPACCA are ORR and PFS by BICR per RECIST.
The Unmet Need in Uncommon EGFR Mutations
Globally, lung cancer is the leading cause of cancer-related deaths among men and women, with NSCLC accounting for approximately 85% of all cases. Mutational activation of EGFR (搜索) is a frequent and early event in NSCLC development. EGFR exon 20 insertion mutations constitute approximately 9% of all EGFR mutations, while PACC mutations represent approximately 12%.
P-loop and αC-helix compressing (PACC) EGFR (搜索) mutations are a distinct set of approximately 70 mostly missense activating mutations within the kinase domain of EGFR, similar to exon 20 insertion mutations in narrowing the drug binding pocket to affect tyrosine kinase inhibitor activity. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need. Patients with PACC mutations have limited treatment options, and there is no broadly utilized standard of care for first-line PACC mutant patients.
ADC Pipeline Advances
ArriVent has initiated Phase 1b dose optimization for ARR-217 (搜索) (MRG007), a cadherin-17 (CDH17 (搜索)) targeted antibody-drug conjugate (ADC), in patients with gastrointestinal malignancies in partnership with Lepu Biopharma (搜索) Co., Ltd. ARR-217 is a glycan-linked, exatecan-based ADC. CDH17 is a membranous cell adhesion molecule frequently overexpressed in colorectal cancer (CRC) and several other gastrointestinal cancers, with limited expression in normal intestinal tissue and pancreatic duct, making it an attractive ADC target. ARR-217 is currently being evaluated in a multi-center Phase 1 study (NCT07066657) assessing safety, tolerability, efficacy, and pharmacokinetics in patients with unresectable locally advanced or metastatic solid tumors.
ARR-002 (AV-P138-ADC) is a first-in-class, Mucin-16 (MUC16 (搜索)) and sodium-dependent phosphate transport protein 2b (NaPi2b (搜索)) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4. Both cell surface antigens are expressed in solid tumors including ovarian and endometrial cancers with limited expression in normal tissues. ArriVent is advancing ARR-002 into the clinic through a first-in-human study evaluating safety, dosing, and early signals of efficacy in patients with ovarian and endometrial cancers, following Investigational New Drug (IND) clearance from the FDA in May 2026. Dosing of the first patient is expected in the third quarter of 2026.
ArriVent also entered into an exclusive licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. (Allist) to develop and commercialize ARR-002 in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan, with all other rights retained by ArriVent.
Financial Position
As of June 30, 2026, ArriVent had cash and investments of $373.1 million, which is expected to fund operations into 2028. Net cash used in operations was $81.5 million for the six months ended June 30, 2026, compared to $94.1 million for the same period in 2025. Research and development expenses were $80.0 million for the six months ended June 30, 2026, versus $89.0 million in the prior-year period. General and administrative expenses were $18.8 million, compared to $11.4 million in 2025. Net loss was $93.2 million for the six months ended June 30, 2026, compared to $95.8 million in the prior-year period.